Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

INTRODUCTION: Recent failures in phase 3 clinical trials in Alzheimer's disease (AD) suggest that novel approaches to drug development are urgently needed. Phase 3 risk can be mitigated by ensuring that clinical efficacy is established before initiating confirmatory trials, but traditional phas...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Dement (N Y)
Autors principals: Satlin, Andrew, Wang, Jinping, Logovinsky, Veronika, Berry, Scott, Swanson, Chad, Dhadda, Shobha, Berry, Donald A.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2016
Matèries:
Featured Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5644271/
https://ncbi.nlm.nih.gov/pubmed/29067290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.01.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars